Do patients prefer transdermal fentanyl or sustained-release oral morphine for treatment of chronic non-cancer pain?
Heidemann, A.J.; Seaton, T.L.
Journal of Family Practice 50(10): 897
2001
ISSN/ISBN: 0094-3509 PMID: 11674896 Document Number: 536680
Document emailed within 1 workday
Related Documents
Wong, J.O.; Chiu, G.L.; Tsao, C.J.; Chang, C.L. 1997: Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain Acta Anaesthesiologica Sinica 35(1): 25-32Tani, M.; Fuku, A.; Terashita, S.; Kashiwagi, H.; Yukawa, H.; Yamaue, H. 2008: Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain Hepato-Gastroenterology 55(86-87): 1545-1548
Yamazaki, M.; Aoki, T.; Tachibana, M.; Akashi, T. 2006: Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(2): 217-221
Yu, S-ying.; Sun, Y.; Wu, Y-long.; Qin, S-kui.; Xie, G-ru.; Liu, S-jun.; Sui, G-jie.; Zhang, H-chun. 2005: Transdermal fentanyl for the management of cancer pain: a survey of 4492 patients Zhonghua Zhong Liu Za Zhi 27(6): 369-372
Thienthong, S.; Krisanaprakornkit, W.; Taesiri, W.; Thaninsurat, N.; Utsahapanich, S.; Klaichanad, C. 2004: Two doses of oral sustained-release tramadol do not reduce pain or morphine consumption after modified radical mastectomy: a randomized, double blind, placebo-controlled trial Journal of the Medical Association of Thailand 87(1): 24-32
Iconomou, G.; Viha, A.; Vagenakis, A.G.; Kalofonos, H.P. 2000: Transdermal fentanyl in cancer patients with moderate-to-severe pain: a prospective examination Anticancer Research 20(6c): 4821-4824
Palm, S.; Moenig, H.; Maier, C. 1997: Effects of oral treatment with sustained release morphine tablets on hypothalamic-pituitary-adrenal axis Methods and Findings in Experimental and Clinical Pharmacology 19(4): 269-273
Satoshi, I.; Narita, M.; Ozeki, A.; Nakamura, A.; Hashimoto, S.; Narita, M.; Kuzumaki, N.; Uezono, Y.; Suzuki, T. 2008: Difference in tolerance to anti-hyperalgesic effect and its molecular mechanisms between chronic treatment with morphine, fentanyl and oxycodone in a chronic pain-like state Nihon Shinkei Seishin Yakurigaku Zasshi 28(5-6): 169-176
Lorvidhaya, V.; Katanyoo, K.; Srisomboon, J.; Suprapaphorn, P.; Cheewakriangkrai, C. 2004: Evaluation of safety and efficacy of transdermal therapeutic system-fentanyl in adult patients with gynecological cancer-related pain Journal of the Medical Association of Thailand 87(3): 319-325
Imai, S.; Narita, M.; Hashimoto, S.; Nakamura, A.; Miyoshi, K.; Nozaki, H.; Hareyama, N.; Takagi, T.; Suzuki, M.; Narita, M.; Suzuki, T. 2006: Differences in tolerance to anti-hyperalgesic effects between chronic treatment with morphine and fentanyl under a state of pain Nihon Shinkei Seishin Yakurigaku Zasshi 26(5-6): 183-192
Mosser, K.H. 1992: Transdermal fentanyl in cancer pain American Family Physician 45(5): 2289-2294
Kaiko, R.F. 1993: Use of transdermal fentanyl for cancer pain management American Family Physician 47(4): 729-730
Yoshitake, A.; Yamamoto, T.; Susaki, S.; Abe, E. 2014: Opioid combination of transdermal fentanyl and oral oxycodone for pain in a patient with giant-cell tumor of the sacrum Masui. Japanese Journal of Anesthesiology 63(2): 199-202
Breitbart, W.; Chandler, S.; Eagel, B.; Ellison, N.; Enck, R.E.; Lefkowitz, M.; Payne, R. 2000: An alternative algorithm for dosing transdermal fentanyl for cancer-related pain Oncology 14(5): 695-705; Discussion 705: 709-717
Fujimoto, M.; Sakuyama, T.; Mizutani, Y.; Kuroda, T.; Yanaga, K. 2004: Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31 Suppl. 2: 190-193
Lakdja, F.; Bui, B.N.; Mage, P.; Becouarn, Y.; Maree, D. 1986: Morphine by the rectal route in chronic pain in cancer patients Presse Medicale 15(33): 1684
Burza, M.; Ginobbi, P.; Fusco, G.; Laurenzi, L.; Tirelli, W.; Arcuri, E. 1998: Transdermal route as an alternative to oral administration of opioids in cancer pain La Clinica Terapeutica 149(4): 277-280
Araico, A.; Saadeddin, A.; Torres-Molina, F.; Peris, J.E. 2009: In vivo evaluation of a new sustained-release formulation of morphine Die Pharmazie 64(10): 653-655
Hashizume, T.; Tomiyasu, S.; Yomiya, K.; Yoshimoto, T.; Harada, A.; Matoba, M. 2007: Validity of recommended minimum dose of prior morphine to initiate transdermal fentanyl patch in prescribing information - multicenter survey of on prescriptions by palliative care specialists in Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(6): 897-902
Abbou, C.C.; Lucas, C.; Leblanc, V. 1997: Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(6): 984-995